Adicet Bio Management
Management criteria checks 2/4
Adicet Bio's CEO is Chen Schor, appointed in Sep 2020, has a tenure of 4.25 years. total yearly compensation is $5.97M, comprised of 10.1% salary and 89.9% bonuses, including company stock and options. directly owns 0.16% of the company’s shares, worth €124.21K. The average tenure of the management team and the board of directors is 3.9 years and 3.6 years respectively.
Key information
Chen Schor
Chief executive officer
US$6.0m
Total compensation
| CEO salary percentage | 10.1% |
| CEO tenure | 4.3yrs |
| CEO ownership | 0.2% |
| Management average tenure | 3.9yrs |
| Board average tenure | 3.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$118m |
| Jun 30 2024 | n/a | n/a | -US$137m |
| Mar 31 2024 | n/a | n/a | -US$140m |
| Dec 31 2023 | n/a | n/a | -US$143m |
| Sep 30 2023 | n/a | n/a | -US$143m |
| Jun 30 2023 | n/a | n/a | -US$115m |
| Mar 31 2023 | n/a | n/a | -US$105m |
| Dec 31 2022 | US$4m | US$562k | -US$70m |
| Sep 30 2022 | n/a | n/a | -US$56m |
| Jun 30 2022 | n/a | n/a | -US$48m |
| Mar 31 2022 | n/a | n/a | -US$36m |
| Dec 31 2021 | US$10m | US$536k | -US$62m |
| Sep 30 2021 | n/a | n/a | -US$55m |
| Jun 30 2021 | n/a | n/a | -US$56m |
| Mar 31 2021 | n/a | n/a | -US$54m |
| Dec 31 2020 | US$11m | US$499k | -US$37m |
Compensation vs Market: Chen's total compensation ($USD5.97M) is above average for companies of similar size in the German market ($USD468.18K).
Compensation vs Earnings: Chen's compensation has increased whilst the company is unprofitable.
CEO
Chen Schor (52 yo)
4.3yrs
Tenure
US$5,973,807
Compensation
Mr. Chen Schor, MBA, BA, CPA, serves as Chair of Carbon Biosciences, Inc. He has been the Chief Executive Officer, President & Director at Adicet Bio, Inc since September 15, 2020. He was a Co-Founder of r...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 4.3yrs | US$5.97m | 0.16% € 124.2k | |
| Founder & Independent Director | no data | US$240.29k | 1.04% € 788.8k | |
| Chief Financial Officer | 4.3yrs | US$2.13m | 0.068% € 51.7k | |
| Chief Technology Officer | 4.2yrs | US$2.09m | 0.043% € 32.4k | |
| Senior VP & Chief Scientific Officer | 3.7yrs | US$2.48m | 0.031% € 23.4k | |
| Chief Human Resource Officer | 2.9yrs | no data | no data | |
| Senior VP & Chief Regulatory Officer | 2.1yrs | no data | no data |
3.9yrs
Average Tenure
62yo
Average Age
Experienced Management: 1IJA's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 4.3yrs | US$5.97m | 0.16% € 124.2k | |
| Founder & Independent Director | 4.3yrs | US$240.29k | 1.04% € 788.8k | |
| Independent Chairman | 4.3yrs | US$275.29k | 0.0072% € 5.4k | |
| Independent Director | 4.3yrs | US$254.29k | 0.013% € 10.0k | |
| Independent Director | 3.8yrs | US$255.29k | 0.0072% € 5.4k | |
| Independent Director | 4.3yrs | US$240.29k | 0.0072% € 5.4k | |
| Member of Scientific Advisory Board | 3.4yrs | no data | no data | |
| Director | less than a year | US$2.90m | 0.12% € 94.5k | |
| Member of Scientific Advisory Board | 3.4yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.4yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.4yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.4yrs | no data | no data |
3.6yrs
Average Tenure
67yo
Average Age
Experienced Board: 1IJA's board of directors are considered experienced (3.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 01:40 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Adicet Bio, Inc. is covered by 11 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Justin Zelin | B. Riley Securities, Inc. |
| John Newman | Canaccord Genuity |
| Yatin Suneja | Guggenheim Securities, LLC |